Independent validation of the PAM50-based Chemo-Endocrine Score (CES) in hormonal receptor positive (HR+)/HER2+ breast cancer (BC) treated with neoadjuvant anti-HER2-based therapy.
         Google Scholar   
Citation:
Cancer Res vol 78 (4 Supplement) P2-09-05
Meeting Instance:
SABCS 2017
Year:
2018
Type:
Abstract
Sub type:
Poster Discussion
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Parents:
None
Children:
3314  
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, BCRF  
Corr. Author:
 
Authors:
                                 
Networks:
LAPS-MA036, LAPS-NC007   
Study
CALGB-40601
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: